Entity

Time filter

Source Type


Zhu J.-Z.,Shanghai JiaoTong University | Zhang J.,Shanghai Pharmaceuticals Holding Co. | Yang K.,Shanghai JiaoTong University | Du R.,Shanghai JiaoTong University | And 3 more authors.
Nephrology Dialysis Transplantation | Year: 2012

BackgroundPatients afflicted with chronic kidney disease (CKD) typically suffer from cardiovascular disease (CVD) which is a leading cause of patient mortality. It has been demonstrated that two distinct physiological events contribute to this disease state. These include the abundance of abnormally high levels of protein-bound uraemic toxins as well as functionally aberrant endothelial progenitor cells (EPCs). Specifically, it has been demonstrated that the uraemic toxin p-cresol (pC; 4-methylphenol) inhibits EPC proliferation and tube formation in previous in vitro studies. More recently, however, it has been demonstrated that circulating pC is actually conjugated and that p-cresylsulphate (pCS) is its main metabolite. Therefore, within the context of this study, we examined the in vitro effects of pC and pCS treatment on cultured human EPCs.MethodsLate-outgrowth EPCs were treated with physiological concentrations of pC or pCS (10, 40, 80, and 160 or 10, 40, 80, 160 and 320 μg/mL for up to 72 h, respectively) in the presence of 4% human serum albumin (HSA). Cell proliferation was determined using WST-1 assay, while migration and tube formation assays were used to evaluate EPC function in vitro. Cell cycle analyses were also performed to determine the effects of pC and pCS on cell cycle status.ResultsWith regard to EPC proliferation, data demonstrate that pC in the presence or absence of HSA had an IC50 of 80.1 and 100.8 μg/mL 72 h post-treatment, respectively, while pCS-treated groups did not impair EPC proliferation. Similarly, pC-treated groups showed limited vessel formation and migration compared with controls and no detrimental effects were seen with pCS treatment. Lastly, pC treatment of EPCs caused cells to accumulate in the G2/M phase of the cell cycle with accompanied down-regulation of cyclin B1 and phosphorylated CDK1. pCS had no effect on cell cycle parameters.ConclusionsOur data demonstrate that pC and pCS have different effects on EPC function. Since there is a dearth of data that have focused on the toxicity of pCS, further research should be performed to determine the exact biological toxicity of pCS on the cardiovascular system. © 2012 The Author. Source


Patent
Zhejiang University and Shanghai Pharmaceuticals Holding Co. | Date: 2012-07-27

Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.


Patent
Changzhou Pharmaceutical Factory and Shanghai Pharmaceuticals Holding Co. | Date: 2013-06-21

The present invention relates to a compound solid preparation and the preparation method therefor and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared by preparing wet valsartan particles from a mixture obtained by mixing valsartan and a pharmaceutic adjuvant with an ethanol aqueous solution as a wetting agent and drying the wet valsartan particles. The amlodipine premix is prepared by mixing amlodipine and a pharmaceutic adjuvant. The valsartan-amlodipine compound solid preparation according to the present invention and the preparation method thereof can prevent the two main ingredients, amlodipine and valsartan, from interfering each other, and the preparation method is relatively simple and suitable for large-scale industrial production.


Patent
Shanghai Pharmaceuticals Holding CO. and Mitsubishi Group | Date: 2013-09-13

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R


Sph

Trademark
Shanghai Pharmaceuticals Holding Co. | Date: 2014-04-11

PHARMACEUTICAL PREPARATIONS AND TRADITIONAL CHINESE MEDICINES USED AS PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS OF THE CARDIOVASCULAR SYSTEM, IMMUNE SYSTEM, METABOLIC SYSTEM AND GASTRO-INTESTINAL SYSTEM; PHARMACEUTICAL PREPARATIONS FOR THE PREVENTION AND TREATMENT OF NEUROPSYCHIATRIC DISEASES AND DISORDERS, VIRAL AND INFECTIOUS DISEASES, AND CANCER; PHARMACEUTICALS AND TRADITIONAL CHINESE MEDICINES USED AS PHARMACEUTICALS, NAMELY, ANTI-INFECTIVES AND ANTINEOPLASTICS. BLOOD PRESSURE AND DIABETIC DIAGNOSTIC MEDICAL DEVICES; MEDICAL DEVICES IN THE NATURE OF INTEGRATED MEDICAL EXAMINATION SYSTEMS COMPRISING MEDICAL DEVICES AND COMPUTER SOFTWARE FOR INFORMATION MANAGEMENT FOR USE IN WEB-BASED PHYSICAL EXAMINATION AND ASSESSMENT OF PATIENTS IN A REMOTE, CLINICAL SETTING; MEDICAL DEVICES FOR DETECTING CANCER; MEDICAL DEVICE, NAMELY, A REMOTE MANIPULATION SYSTEM CONSISTING OF A ROBOTIC ARM, KNOB, DEFLECTION LEVER, AND BUTTONS, TO FACILITATE REMOTE CATHETERIZATIONS; MEDICAL DEVICES AND APPARATUS, NAMELY, MEDICAL GUIDEWIRES AND PARTS AND FITTINGS THEREFOR; MEDICAL DEVICES FOR MONITORING BLOOD PROPERTIES AND RESPIRATORY EVENTS; MEDICAL DEVICES FOR MONITORING OXYMETORY, GAS ANALYSIS AND VITAL SIGNS; MEDICAL DEVICES FOR MONITORING OXYMETORY, GAS ANALYSIS, VITAL SIGNS, BLOOD PROPERTIES AND RESPIRATORY EVENTS; MEDICAL DEVICES FOR MONITORING VITAL SIGNS, BLOOD PROPERTIES AND RESPIRATORY EVENTS; MEDICAL DEVICES FOR TREATING VASCULAR BIFURCATIONS; MEDICAL DEVICES FOR MONITORING OXYMETORY, GAS ANALYSIS, VITAL SIGNS, BLOOD PROPERTIES AND RESPIRATORY EVENTS AND SOFTWARE SOLD AS A UNIT THEREWITH; MEDICAL DEVICES FOR MONITORING OXYMETORY, GAS ANALYSIS, VITAL SIGNS, BLOOD PROPERTIES AND RESPIRATORY EVENTS AND SYSTEM THAT TRANSMIT THE DATA THROUGH THE INTERNET; MEDICAL DEVICES FOR USE IN CANNULATION OR TO STEM THE FLOW OF TRAUMATIC BLEEDING, NAMELY, TOURNIQUETS; MEDICAL DEVICES FOR KEGEL EXERCISES, NAMELY, PELVIC FLOOR EXERCISERS FOR USE TO TREAT SYMPTOMS OF URINARY INCONTINENCE AND FOR THERAPEUTIC PURPOSES; MEDICAL DEVICES FOR PLACING AND SECURING CATHETERS; MEDICAL DEVICES, NAMELY, INFUSION PUMPS FOR DELIVERING MEASURED AMOUNTS OF SOLUTIONS INTO THE BLOODSTREAM OVER TIME; MEDICAL DEVICES, NAMELY, PULSE OXIMETERS; PORTABLE MEDICAL DEVICES USED FOR BREATHING EXERCISES, NAMELY, PORTABLE DEVICES USED FOR ENDOGENOUS BREATHING EXERCISES AND FOR RESPIRATORY MUSCLE TRAINING. RETAIL MEDICAL DEVICE STORES; RETAIL STORE SERVICES FEATURING PHARMACEUTICALS; RETAIL PHARMACY SERVICES; ON-LINE RETAIL STORE SERVICES FEATURING PHARMACEUTICALS AND MEDICAL DEVICES.

Discover hidden collaborations